This aligns with the interpretation that NfL reflects disease aggressiveness, rather than staging, and that combining Aβ and NfL levels can help characterize whether an individual is on the AD pathway and the disease aggressiveness (Jung and Damoiseaux 2024). The gene discussed is NEFL; the disease is Alzheimer disease.